Supplemental Material for Juurakko et al., 2021 by Collin L. Juurakko (10941459)

“…</p><p></p><p></p><p> </p><p>A list of protein accession identifications for all significantly increased and decreased proteins obtained by MS were assembled and used as inputs for STRING (version 11.0) to predict protein-protein interactions (Franceschini <i>et al.…”

SLE progression is accompanied by highly specific blockade of cytokine-induced STAT signaling and target gene induction. by Matthew B. Hale (260700)

“…<p>(A) Detailed analysis of 24 signaling nodes. Data points are averaged from three mice; error bars represent standard deviation. …”

Mean response rate indicating the velocity of illusory movement, Run 1 and Run 2 combined data (N = 12). by Tatjana Seizova-Cajic (80195)

“…The velocity computed this way steadily decreases throughout the vibration period. <i>Triangles</i>: Means were computed only for periods in which movement was perceived (i.e., zeros were excluded) separately for illusory extension (positive sign) and flexion (negative sign). …”

Epileptiform activity induces opposite changes in the RRP and P_rel. by Carlo Natale Giuseppe Giachello (380180)

“…<p>(A,B) Cumulative curves of EPSP amplitudes evoked at 10 Hz at different time-points. The linear part was fitted as described in Methods. …”

Perfusion of substance P (15 μM) had no effect on the amplitude or slope of the fEPSP recorded from the CA1 region of the rat hippocampal slice by Kerrie N Wease (12951)

“…(b) and (c) Pooled time course data showing the lack of effect of substance P on the slope (b) and amplitude (c) of the fEPSP. Points represent mean ± s.e.m., n = 4. Scale bar represents 0.5 mV and 10 ms.…”

Transcriptional response of components of the Cu efflux network and phenotypic consequences of their deletion. by W. Lee Pang (102290)

“…Expression of the metalloregulator <i>VNG1179C</i> does not change, suggesting that it is post-transcriptionally activated. Error bars are s.e.m for n = 5. Points (X) within each expression profile were normalized to the expression value at t = 0 (X₀). …”

PTEN expression in mitochondrial and cytosolic fraction after the excitotoxic stimulus. by Valentina Grande (647515)

“…Data are expressed as mean ± S.E.M., *<i>P</i><0.05, #<i>P</i><0.05, **<i>P</i><0.01 with Two way ANOVA and Bonferroni post hoc test. …”

Effect of ECFCs and astrocytes-ECFCs on 3D GBM migration. by R. Marisol Herrera-Perez (4993793)

The effect of ranibizumab and aflibercept injected intraperitoneally into neonatal mice. by Yusuke Ichiyama (11237783)

“…(F-I) The high magnification images of the whole-mounted retinas show decreased number of branching points, increased area of regressed capillaries (filled arrowheads), and decreased number of proliferating ECs (open arrowheads) in the aflibercept group but not in the ranibizumab groups. …”

G-chart of Diagnosis Dates of Cancer. by Harald Schrem (578639)

“…Cases marked by the letter “B” and a red dot on the lower control limit (LCL) indicate a failed Benneyan test pointing to statistically relevant increases in the diagnostic event rate which should trigger clinical concerns in regard to causation, e.g. by intensified or uncontrolled immunosuppression. …”

Astrocytes increase the migration GBM cells in a 3D-brain-like model. by R. Marisol Herrera-Perez (4993793)

Robotic-Assisted Median Arcuate Ligament Release With Celiac Artery Lysis and Celiac Ganglion Neurolysis by G. Kimble Jett (6509428)

“…<a href="https://doi.org/10.1016/j.jvs.2008.12.078"><em>J Vasc Surg</em>. 2009;50:124-133.…”

Table_8_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_6_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_10_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_2_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

P4HA3 deficiency increased sensitization to immune checkpoint inhibitors and P4HA3 could predict the clinical therapeutic effect of PD-1 inhibitor (Camrelizumab). by Hong Yan Huang (20135965)

“…(B) P4HA3 deficiency inhibited proliferation ability of MDA-MB-231, HCT116 and A549 cell lines by EdU assay. Scale bar: 50 μm. …”

Table_7_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_13_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”